An object of the present invention is to provide a senescence retarding agent that delays the onset of senescence symptoms and extends longevity, and is superior in safety. The senescence retarding agent of the present invention that achieves the object is characterized by containing a plant fermentation product as an active ingredient, the plant fermentation product being a mixture of the following: (a) a koji mold-fermented product of one or more kinds of beans and/or cereals selected from the group consisting of barley, black soybean, red rice, black rice, adzuki bean, adlay, Japanese millet, foxtail millet, and millet; (b) a yeast- and/or lactic acid bacterium-fermented product of one or more kinds of fruits selected from the group consisting of mikan (mandarin orange), grape, apple, yama-budo (crimson glory grape), peach, kaki (Japanese persimmon), papaya, nashi (Japanese pear), watermelon, ume (Japanese apricot), fig, karin (Chinese quince), pumpkin, kumquat, yuzu (Chinese lemon), loquat, apricot, jujube, chestnut, matatabi (silvervine), and sumomo (Japanese plum); (c) a yeast- and/or lactic acid bacterium-fermented product of one or more kinds of root crops and/or potatoes selected from the group consisting of murasaki-imo (purple sweet potato), kikuimo (Jerusalem artichoke), carrot, onion, satsuma-imo (sweet potato), satoimo (taro), jinenzyo (Japanese yam), daikon (Japanese radish), akakabu (red turnip), gobo (burdock root), renkon (lotus root), yacon, yuri-ne (lily bulb), kuwai (arrowhead), ginger, garlic, and turmeric; (d) a yeast- and/or lactic acid bacterium-fermented product of one or more kinds of flowers and/or leaf vegetables selected from the group consisting of cabbage, shiso (perilla), mulberry leaves, dokudami (Korean houttuynia), yomogi (wormwood), kumazasa (kuma bamboo grass), and dandelion; (e) a yeast- and/or lactic acid bacterium-fermented product of one or more kinds of seaweeds selected from the group consisting of kombu (sea tangle), wakame (Undaria pinnatifida), and mozuku (Nemacystus decipiens); (f) a yeast- and/or lactic acid bacterium-fermented product of one or more kinds of seeds selected from the group consisting of black sesame seeds, walnuts, and ginkgo nuts; and (g) a yeast- and/or lactic acid bacterium-fermented product of one or two kinds of mushrooms selected from the group consisting of maitake (Grifola frondosa) and shiitake (Lentinus edodes).

A process for preparing a total extract which is a mixture of a fresh plant matter with a fatty matter includes a. contacting the fresh plant matter which comprises at least 10% of water by weight relative to its total weight before or after desiccation loss, with the fatty matter chosen from hydrogenated oil or fat at a temperature between 50° C. and 180° C.; b. grinding the plant matter-fatty matter mixture at said temperature between 50° C. to 180° C.; and c. recovering a total extract that is solid or liquid at ambient temperature with a concentration of less than or equal to 4% of water by weight relative to the total weight of the total extract. Extracts recovered from such process and treatments using the extracts are also disclosed.

A process for preparing a total extract which is a mixture of a fresh plant matter with a fatty matter includes a. contacting the fresh plant matter which comprises at least 10% of water by weight relative to its total weight before or after desiccation loss, with the fatty matter chosen from hydrogenated oil or fat at a temperature between 50° C. and 180° C.; b. grinding the plant matter-fatty matter mixture at said temperature between 50° C. to 180° C.; and c. recovering a total extract that is solid or liquid at ambient temperature with a concentration of less than or equal to 4% of water by weight relative to the total weight of the total extract. Extracts recovered from such process and treatments using the extracts are also disclosed.

Disclosed herein are pharmaceutical compositions and uses thereof in treating muscle atrophy. The pharmaceutical composition comprises an ethanol extract of an herbal mixture consisting of Artemisia argyi, Morus alba L., Leonurus japonicus Houtt, Capsicum annuum L., Lophatherum gracile Brongn, Curcuma longa, and Glycyrrhiza uralensis; and a pharmaceutically acceptable excipient. The ethanol extract comprise 14 ingredients, including chlorogenic acid, leonurine, schaftoside, rutin, isochaftoside, isochlorogenic acid, 4, 5-dicaffeoylquinic acid, quercetin, apigenin, glycyrrhizic acid, bisdemethoxycurcumin, demethoxycurcumin, curcumin and artemisetin.

Disclosed herein are pharmaceutical compositions and uses thereof in treating muscle atrophy. The pharmaceutical composition comprises an ethanol extract of an herbal mixture consisting of Artemisia argyi, Morus alba L., Leonurus japonicus Houtt, Capsicum annuum L., Lophatherum gracile Brongn, Curcuma longa, and Glycyrrhiza uralensis; and a pharmaceutically acceptable excipient. The ethanol extract comprise 14 ingredients, including chlorogenic acid, leonurine, schaftoside, rutin, isochaftoside, isochlorogenic acid, 4, 5-dicaffeoylquinic acid, quercetin, apigenin, glycyrrhizic acid, bisdemethoxycurcumin, demethoxycurcumin, curcumin and artemisetin.

Disclosed herein are pharmaceutical compositions and uses thereof in treating muscle atrophy. The pharmaceutical composition comprises an ethanol extract of an herbal mixture consisting of Artemisia argyi, Morus alba L., Leonurus japonicus Houtt, Capsicum annuum L., Lophatherum gracile Brongn, Curcuma longa, and Glycyrrhiza uralensis; and a pharmaceutically acceptable excipient. The ethanol extract comprise 14 ingredients, including chlorogenic acid, leonurine, schaftoside, rutin, isochaftoside, isochlorogenic acid, 4, 5-dicaffeoylquinic acid, quercetin, apigenin, glycyrrhizic acid, bisdemethoxycurcumin, demethoxycurcumin, curcumin and artemisetin.

The present invention provides a composition comprising lycopene, one or both of phytoene and phytofluene, and phytosterols, wherein the concentration of lycopene is in the range of 0.3%-2% (w/w) and wherein the weight ratio of said lycopene to one or both of phytoene and phytofluene is in the range of 1:1 to 1:2.5. The invention also encompasses a method for preparing said composition.

The present invention provides a composition comprising lycopene, one or both of phytoene and phytofluene, and phytosterols, wherein the concentration of lycopene is in the range of 0.3%-2% (w/w) and wherein the weight ratio of said lycopene to one or both of phytoene and phytofluene is in the range of 1:1 to 1:2.5. The invention also encompasses a method for preparing said composition.

An anti-aging composition comprising: pinebark extract, polypodium leucotomos, ashwagandha extract, dehydroepiandrosterone, white tea extract, alpha lipoic acid, vitamin K2, bioactive silicon, hyaluronic acid, trimethylglycine, and optionally, piperine, green tea extract, folic acid, vitamin C, camu camu, and blueberry extract.

An anti-aging composition comprising: pinebark extract, polypodium leucotomos, ashwagandha extract, dehydroepiandrosterone, white tea extract, alpha lipoic acid, vitamin K2, bioactive silicon, hyaluronic acid, trimethylglycine, and optionally, piperine, green tea extract, folic acid, vitamin C, camu camu, and blueberry extract.